Abstract:Cancer immunotherapy with ICB is considered a promising strategy for cancer treatment. In silico prediction of the ICB response is an important step toward achieving effective and personalized cancer immunotherapy. Three challenging issues remain: (i) Identifying highly predictive biomarkers by deciphering and understanding the interaction between tumor and immune cells; (ii) efficiently obtaining and predicting these biomarkers using HTS data; and (iii) building effective computational models that integrate these biomarkers for improved ICB response prediction. Cancer immunotherapy with immune-checkpoint blockade (ICB) is considered a promising strategy for cancer treatment. Identifying predictive biomarkers and developing efficient computational models to predict the ICB response are important issues for successful immunotherapy. Here, we present a concise and intuitive survey of the computational issues for ICB response prediction, providing a summary of the available predictive biomarkers and building of one-stop machine-learning models that integrate biomarkers calculable from high-throughput sequencing (HTS) data. Several points for discussion are highlighted to inspire further research for improving ICB treatment. Continuing efforts are required to improve ICB response prediction and to identify novel predictive biomarkers by taking advantage of the rapid development of computational models and HTS techniques for effective and personalized cancer immunotherapy. Cancer immunotherapy with immune-checkpoint blockade (ICB) is considered a promising strategy for cancer treatment. Identifying predictive biomarkers and developing efficient computational models to predict the ICB response are important issues for successful immunotherapy. Here, we present a concise and intuitive survey of the computational issues for ICB response prediction, providing a summary of the available predictive biomarkers and building of one-stop machine-learning models that integrate biomarkers calculable from high-throughput sequencing (HTS) data. Several points for discussion are highlighted to inspire further research for improving ICB treatment. Continuing efforts are required to improve ICB response prediction and to identify novel predictive biomarkers by taking advantage of the rapid development of computational models and HTS techniques for effective and personalized cancer immunotherapy. immune checkpoints are molecules in the immune system that either enhance or attenuate a signal. Tumors protect themselves from the immune system by inhibiting the T cell signal. The use of inhibitors to block inhibitory checkpoint molecules by recovering the anticancer immune response is referred to as ‘immune checkpoint blockade’. peptides presented by MHC class I or MHC class II molecules on the tumor cell surface. These peptides derive from tumor-specific somatic mutations and are not expressed in normal cells. the cellular environment in which the tumor exists, including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signaling molecules, and the extracellular matrix. The tumor and surrounding microenvironment are closely related and constantly interact. Effective immunotherapy often requires changes to the TME. V-J recombination is the unique mechanism of genetic recombination that occurs in developing lymphocytes during the early stages of T and B cell maturation. It involves somatic recombination in a nearly random fashion, which rearranges variable (V), joining (J), and, in some cases, diversity (D) gene segments. This has resulted in the highly diverse repertoire of antibodies and/or immunoglobulins (Igs) and T cell receptors (TCRs) found on B cells and T cells, respectively.

Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy

Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules

Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Associations Between Interaction Effects of Mutational Events and Efficient Immunotherapy in Squamous NSCLC: Results from 373 Patients.

A Novel Immunogenic Cell Death-Related Genes Signature for Predicting Prognosis, Immune Landscape and Immunotherapy Effect in Hepatocellular Carcinoma.

PathwayTMB: A pathway-based tumor mutational burden analysis method for predicting the clinical outcome of cancer immunotherapy

Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer

Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy

Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer

Towards in Silico Prediction of the Immune-Checkpoint Blockade Response

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy

Predictive Biomarkers for Tumor Immune Checkpoint Blockade

The Emerging Development of Tumor Mutational Burden in Patients with NSCLC.

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers

Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma

The emerging development of tumor mutational burden in patients with NSCLC

Therapeutic Guidance of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Comprehensive Meta-analysis